Oral Insulin

• Product Class: Protein

• Indication: Type I and II Diabetes

• Partnership Status: Discussions ongoing

• Development Status: Phase II studies ongoing

• CY01 Accomplishments: Euglycemic Clamp Study completed; 90-day toxicology studies initiated; fed/fast study initiated

• Upcoming CY02 Milestones: Additional Phase II data; development of tablet formulation

Previous slide

Next slide

Back to first slide

View graphic version